Jiangsu Bioperfectus Technologies Co Ltd
688399
Company Profile
Business description
Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products portfolio includes Fever respiratory pathogen detection series, Fever with a rash pathogen test series, Fever with bleeding pathogen test series, Foodborne diseases and diarrheal pathogen detection and Other types of pathogen detection series.
Contact
3rd floor, Block G19, No.1 Yaocheng Avenue
Jiangsu
Taizhou
CHNT: +86 52386201616
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
592
Stocks News & Analysis
stocks
Overpriced ASX listed consumer electronics retailers
Solid balance sheets, lower business risk and strong sales but investors are overly optimistic.
stocks
Nvidia and AMD: Maintain fair value estimate amid reports of Meta’s negotiations to buy Google TPUs
Our update on select stocks from the Semiconductors industry.
stocks
Alphabet: Gemini momentum and possible Meta TPU deal underscore AI capability
We think Alphabet is exceptionally well positioned in everything AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,927.90 | 18.80 | 0.21% |
| CAC 40 | 8,096.43 | 70.63 | 0.88% |
| DAX 40 | 23,726.22 | 261.59 | 1.11% |
| Dow JONES (US) | 47,427.12 | 1,181.71 | 2.56% |
| FTSE 100 | 9,691.58 | 82.05 | 0.85% |
| HKSE | 25,928.08 | 33.53 | 0.13% |
| NASDAQ | 23,214.69 | 189.10 | 0.82% |
| Nikkei 225 | 49,559.07 | 899.55 | 1.85% |
| NZX 50 Index | 13,581.33 | 19.32 | 0.14% |
| S&P 500 | 6,812.61 | 46.73 | 0.69% |
| S&P/ASX 200 | 8,634.00 | 19.10 | 0.22% |
| SSE Composite Index | 3,864.18 | 5.84 | -0.15% |